Our research focuses on enhancing antimicrobial drug discovery – covering aspects from early target validation to detailed characterisation studies of novel antimicrobial substances. We develop fast and predictive high-throughput screening (HTS) tools, for example, by using bacterial bioreporters, and use combinations of target- and cell-based approaches in our screening campaigns. Through collaborations, our expertise in screening technologies and assay development is also employed in other therapeutic areas. We place special emphasis on using natural products (NP) and NP-inspired synthetic compounds in screening to facilitate their integration into HTS campaigns.
Päivi Tammela, Unit Leader
PhD (Pharm), Adjunct professor in pharmaceutical biology. She is leading the Bioactivity Screening Group and is expert in bioassay development and screening technologies especially in antimicrobial drug discovery. Academy of Finland Research Fellow position (2014-2019).